Abstract
Introduction: Immunocompromised patients, especially those hospitalized, are at a higher risk for infection with opportunistic pathogens such as Stenotrophomonas maltophilia (S. maltophilia) which is a multidrug-resistant gram-negative bacillus and can cause a challenge in the management of patients with concomitant COVID-19 and S. maltophilia pneumonia.
Case Presentation: A 71-year-old man with Hodgkin's lymphoma presented with severe respiratory symptoms of COVID-19 was intubated upon admission and the initial standard treatment for COVID-19 was started for him. The patient subsequently developed superimposed bacterial pneumonia with S. maltophilia. According to that, the patient's intubation tube was removed and a tracheostomy was performed for him. Also, antibiotic treatment was replaced with Colistin and Co-trimoxazole drugs. Finally, after 31 days of hospitalization in the ICU and the appropriate drug treatment, he was discharged with reduced symptoms and partial recovery.
Conclusion: It should be noted that the occurrence of co-infection with multidrug-resistant pathogens such as S. maltophilia requires proper management to select appropriate treatment methods and drugs, so that in addition to proper effectiveness, it does not lead to side effects and complications associated with COVID-19 disease.
Graphical Abstract
Infectious Disorders - Drug Targets
Title:Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Volume: 21 Issue: 8
Author(s): David Darvishnia, Mahdieh Sadeghi, Ali Sharifpour, Zakaria Zakariaei*, Elham Sadat Banimostafavi, Mahdi Fakhar and Rabeeh Tabaripour
Affiliation:
- Toxicology and Forensic Medicine Division, Orthopedic Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, ,Iraq
Abstract:
Introduction: Immunocompromised patients, especially those hospitalized, are at a higher risk for infection with opportunistic pathogens such as Stenotrophomonas maltophilia (S. maltophilia) which is a multidrug-resistant gram-negative bacillus and can cause a challenge in the management of patients with concomitant COVID-19 and S. maltophilia pneumonia.
Case Presentation: A 71-year-old man with Hodgkin's lymphoma presented with severe respiratory symptoms of COVID-19 was intubated upon admission and the initial standard treatment for COVID-19 was started for him. The patient subsequently developed superimposed bacterial pneumonia with S. maltophilia. According to that, the patient's intubation tube was removed and a tracheostomy was performed for him. Also, antibiotic treatment was replaced with Colistin and Co-trimoxazole drugs. Finally, after 31 days of hospitalization in the ICU and the appropriate drug treatment, he was discharged with reduced symptoms and partial recovery.
Conclusion: It should be noted that the occurrence of co-infection with multidrug-resistant pathogens such as S. maltophilia requires proper management to select appropriate treatment methods and drugs, so that in addition to proper effectiveness, it does not lead to side effects and complications associated with COVID-19 disease.
Export Options
About this article
Cite this article as:
Darvishnia David , Sadeghi Mahdieh , Sharifpour Ali , Zakariaei Zakaria *, Banimostafavi Sadat Elham , Fakhar Mahdi and Tabaripour Rabeeh , Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran, Infectious Disorders - Drug Targets 2021; 21 (8) : e160921191124 . https://dx.doi.org/10.2174/1871526521666210203220718
DOI https://dx.doi.org/10.2174/1871526521666210203220718 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry An Antileukemic Glutaminase Free L-Asparaginase from Bacillus brevis
Current Biotechnology Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Clonetics
Current Drug Metabolism Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Immunological Aspects of Adult T-Cell Leukemia/Lymphoma (ATLL), a Possible Neoplasm of Regulatory T-Cells
Current Immunology Reviews (Discontinued) Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry Acanthamoeba-Bacteria: A Model to Study Host Interaction with Human Pathogens
Current Drug Targets From TGF-β to Cancer Therapy
Current Drug Targets Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Immunotoxins and Other Conjugates: Pre-clinical Studies
Mini-Reviews in Medicinal Chemistry Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy Cancer Electrogene Therapy with Interleukin-12
Current Gene Therapy CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry